[SCHEDULE 13G/A] Royalty Pharma plc SEC Filing
Royalty Pharma plc is reported in this Schedule 13G/A as having certain Class A ordinary shares beneficially owned by General Atlantic and affiliated funds. Collectively, the Reporting Persons hold an indirect interest in 14,243,870 Class A ordinary shares (issuable upon conversion of Class B interests), representing approximately 3.2% of the Class A ordinary shares outstanding based on an aggregate count of 446,536,920 shares.
The schedule shows the Reporting Persons have 0 sole voting and dispositive power and 14,243,870 shares of shared voting and dispositive power, reflecting that the positions are held through General Atlantic (RP) Collections, LLC and multiple General Atlantic investment funds and entities organized in Delaware, Bermuda and Luxembourg. The General Atlantic entities state they constitute a group under Rule 13d-5 and disclose the conversion feature that creates equivalent Class A exposure. The filing does not report ownership above the 5% threshold.
Royalty Pharma plc 猫 indicata in questo Schedule 13G/A come detentrice indiretta, tramite General Atlantic e fondi affiliati, di alcune azioni ordinarie di Classe A. Collegialmente i soggetti segnalanti detengono un interesse indiretto in 14,243,870 azioni ordinarie di Classe A (emettibili a seguito della conversione di partecipazioni di Classe B), rappresentanti circa il 3.2% delle azioni ordinarie di Classe A in circolazione, sulla base di un totale aggregato di 446,536,920 azioni.
Lo Schedule indica che i soggetti segnalanti hanno 0 poteri di voto e di disposizione esclusivi e 14,243,870 azioni con poteri di voto e di disposizione condivisi, a indicare che le posizioni sono detenute tramite General Atlantic (RP) Collections, LLC e molteplici fondi e entit脿 di investimento General Atlantic organizzati in Delaware, Bermuda e Luxembourg. Le entit脿 General Atlantic dichiarano di costituire un gruppo ai sensi della Rule 13d-5 e rendono nota la caratteristica di conversione che genera un'esposizione equivalente alle azioni di Classe A. La comunicazione non riporta una partecipazione superiore alla soglia del 5%.
Royalty Pharma plc figura en este Schedule 13G/A como titular indirecta, a trav茅s de General Atlantic y fondos afiliados, de determinadas acciones ordinarias de Clase A. Conjuntamente, las personas informantes mantienen un inter茅s indirecto en 14,243,870 acciones ordinarias de Clase A (emitibles al convertirse participaciones de Clase B), que representan aproximadamente el 3.2% de las acciones ordinarias de Clase A en circulaci贸n, sobre la base de un total agregado de 446,536,920 acciones.
El Schedule muestra que las personas informantes tienen 0 poder de voto y de disposici贸n exclusivo y 14,243,870 acciones con poder de voto y de disposici贸n compartido, lo que refleja que las posiciones se mantienen a trav茅s de General Atlantic (RP) Collections, LLC y m煤ltiples fondos y entidades de inversi贸n de General Atlantic constituidas en Delaware, Bermuda y Luxembourg. Las entidades de General Atlantic declaran que constituyen un grupo conforme a la Rule 13d-5 y revelan la caracter铆stica de conversi贸n que genera una exposici贸n equivalente a la Clase A. La presentaci贸n no informa de una participaci贸n superior al umbral del 5%.
Royalty Pharma plc電� 氤� Schedule 13G/A鞐� General Atlantic 氚� 攴� 瓿勳棿 韼�霌滊ゼ 韱淀暣 鞚茧秬 韥措灅鞀� A 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚鸽摛鞚� 頃╈硱靹� 韥措灅鞀� B 歆�攵勳潣 鞝勴櫂鞙茧 氚滍枆霅� 靾� 鞛堧姅 14,243,870欤检潣 韥措灅鞀� A 氤错喌欤检棎 雽�頃� 臧勳爲鞝� 歆�攵勳潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 齑� 446,536,920欤检潣 頃╆硠 旮办鞙茧 氚滍枆 欤检嫕鞚� 鞎� 3.2%鞐� 頃措嫻頃╇媹雼�.
頃措嫻 靹滊電� 氤搓碃鞚鸽摛鞚� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潃 0鞚搓碃, 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潃 14,243,870欤检瀯鞚� 氤挫棳欤茧┌, 鞚措姅 頃措嫻 韽靺橂摛鞚� General Atlantic (RP) Collections, LLC 氚� Delaware, Bermuda, Luxembourg鞐� 靹る霅� 氤奠垬鞚� General Atlantic 韴瀽 韼�霌� 氚� 氩曥澑鞚� 韱淀暣 氤挫湢霅橁碃 鞛堨潓鞚� 氚橃榿頃╇媹雼�. General Atlantic 瓿勳棿靷摛鞚� Rule 13d-5鞐� 霐半澕 攴鸽９鞚� 甑劚頃滊嫟瓿� 氚濏瀳瓿�, 韥措灅鞀� A鞕� 霃欕摫頃� 鞚奠姢韽爛毳� 靸濎劚頃橂姅 鞝勴櫂 旮半姤鞚� 瓿奠嫓頃╇媹雼�. 氤� 鞝滌稖靹滊姅 5% 旮办鞚� 齑堦臣頃橂姅 靻岇湢毳� 氤搓碃頃橃 鞎婌姷雼堧嫟.
Royalty Pharma plc est indiqu茅e dans ce Schedule 13G/A comme d茅tenant, via General Atlantic et des fonds affili茅s, certaines actions ordinaires de Classe A 脿 titre b茅n茅ficiaire. Collectivement, les personnes d茅clarante d茅tiennent un int茅r锚t indirect dans 14,243,870 actions ordinaires de Classe A (attribuables lors de la conversion d鈥檌nt茅r锚ts de Classe B), repr茅sentant environ 3.2% des actions ordinaires de Classe A en circulation, sur la base d鈥檜n total agr茅g茅 de 446,536,920 actions.
Le Schedule indique que les personnes d茅clarante disposent de 0 pouvoir exclusif de vote et de disposition et de 14,243,870 actions avec pouvoir partag茅 de vote et de disposition, ce qui refl猫te que les positions sont d茅tenues par l鈥檌nterm茅diaire de General Atlantic (RP) Collections, LLC et de plusieurs fonds et entit茅s d鈥檌nvestissement General Atlantic constitu茅s dans le Delaware, les Bermudes et le Luxembourg. Les entit茅s General Atlantic d茅clarent constituer un groupe au sens de la Rule 13d-5 et divulguent la clause de conversion qui cr茅e une exposition 茅quivalente 脿 la Classe A. Le d茅p么t ne signale pas de participation sup茅rieure au seuil de 5%.
Royalty Pharma plc wird in diesem Schedule 13G/A als wirtschaftlich Inhaber bestimmter Class-A-Stammaktien 眉ber General Atlantic und verbundene Fonds ausgewiesen. Zusammen halten die meldenden Personen ein indirektes Interesse an 14,243,870 Class-A-Stammaktien (ausgebbar bei Umwandlung von Class-B-Beteiligungen), was bei einer Gesamtanzahl von 446,536,920 Aktien etwa 3.2% der ausgegebenen Class-A-Aktien entspricht.
Der Schedule f眉hrt aus, dass die meldenden Personen 0 alleiniges Stimm- und Verf眉gungsrecht und 14,243,870 Aktien gemeinschaftliches Stimm- und Verf眉gungsrecht haben, was widerspiegelt, dass die Positionen 眉ber General Atlantic (RP) Collections, LLC und mehrere in Delaware, Bermuda und Luxembourg gegr眉ndete General Atlantic-Investmentfonds und -Einheiten gehalten werden. Die General Atlantic-Einheiten geben an, nach Rule 13d-5 eine Gruppe zu bilden und legen die Umwandlungsbestimmung offen, die eine gleichwertige Class-A-Exponierung erzeugt. Die Einreichung berichtet keinen Anteil 眉ber der 5%-Schwelle.
- None.
- None.
Insights
TL;DR: General Atlantic reports a modest, non-controlling ~3.2% economic exposure via convertible interests; transparency aids investor ownership clarity.
The disclosed 14,243,870 share interest is derived from Class B interests convertible into Class A shares, producing an economic exposure equal to ~3.2% of Class A on the stated basis of 446,536,920 aggregate shares. Because sole voting and dispositive power are reported as 0 and the position is shown as shared, the immediate market-moving influence is limited. The filing is useful for tracking potential dilution and aggregation of related-party positions but does not indicate a controlling stake or greater-than-5% ownership that would typically prompt material corporate influence.
TL;DR: Group designation and shared voting power are disclosed, but aggregate holdings remain below material control thresholds.
The Schedule 13G/A identifies multiple General Atlantic entities that together may be deemed a "group" under Rule 13d-5, clarifying who holds the convertible interests and how voting/dispositive power is allocated. Shared voting and dispositive power of 14,243,870 and sole power of 0 indicate coordination potential without unilateral control. The reporting of entity jurisdictions (Delaware, Bermuda, Luxembourg) and the chain of fund relationships improves transparency about who could influence votes if conversion or internal reallocation occurs, but the position as disclosed does not meet common materiality thresholds for control.
Royalty Pharma plc 猫 indicata in questo Schedule 13G/A come detentrice indiretta, tramite General Atlantic e fondi affiliati, di alcune azioni ordinarie di Classe A. Collegialmente i soggetti segnalanti detengono un interesse indiretto in 14,243,870 azioni ordinarie di Classe A (emettibili a seguito della conversione di partecipazioni di Classe B), rappresentanti circa il 3.2% delle azioni ordinarie di Classe A in circolazione, sulla base di un totale aggregato di 446,536,920 azioni.
Lo Schedule indica che i soggetti segnalanti hanno 0 poteri di voto e di disposizione esclusivi e 14,243,870 azioni con poteri di voto e di disposizione condivisi, a indicare che le posizioni sono detenute tramite General Atlantic (RP) Collections, LLC e molteplici fondi e entit脿 di investimento General Atlantic organizzati in Delaware, Bermuda e Luxembourg. Le entit脿 General Atlantic dichiarano di costituire un gruppo ai sensi della Rule 13d-5 e rendono nota la caratteristica di conversione che genera un'esposizione equivalente alle azioni di Classe A. La comunicazione non riporta una partecipazione superiore alla soglia del 5%.
Royalty Pharma plc figura en este Schedule 13G/A como titular indirecta, a trav茅s de General Atlantic y fondos afiliados, de determinadas acciones ordinarias de Clase A. Conjuntamente, las personas informantes mantienen un inter茅s indirecto en 14,243,870 acciones ordinarias de Clase A (emitibles al convertirse participaciones de Clase B), que representan aproximadamente el 3.2% de las acciones ordinarias de Clase A en circulaci贸n, sobre la base de un total agregado de 446,536,920 acciones.
El Schedule muestra que las personas informantes tienen 0 poder de voto y de disposici贸n exclusivo y 14,243,870 acciones con poder de voto y de disposici贸n compartido, lo que refleja que las posiciones se mantienen a trav茅s de General Atlantic (RP) Collections, LLC y m煤ltiples fondos y entidades de inversi贸n de General Atlantic constituidas en Delaware, Bermuda y Luxembourg. Las entidades de General Atlantic declaran que constituyen un grupo conforme a la Rule 13d-5 y revelan la caracter铆stica de conversi贸n que genera una exposici贸n equivalente a la Clase A. La presentaci贸n no informa de una participaci贸n superior al umbral del 5%.
Royalty Pharma plc電� 氤� Schedule 13G/A鞐� General Atlantic 氚� 攴� 瓿勳棿 韼�霌滊ゼ 韱淀暣 鞚茧秬 韥措灅鞀� A 氤错喌欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃� 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 氤搓碃鞚鸽摛鞚� 頃╈硱靹� 韥措灅鞀� B 歆�攵勳潣 鞝勴櫂鞙茧 氚滍枆霅� 靾� 鞛堧姅 14,243,870欤检潣 韥措灅鞀� A 氤错喌欤检棎 雽�頃� 臧勳爲鞝� 歆�攵勳潉 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 齑� 446,536,920欤检潣 頃╆硠 旮办鞙茧 氚滍枆 欤检嫕鞚� 鞎� 3.2%鞐� 頃措嫻頃╇媹雼�.
頃措嫻 靹滊電� 氤搓碃鞚鸽摛鞚� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潃 0鞚搓碃, 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潃 14,243,870欤检瀯鞚� 氤挫棳欤茧┌, 鞚措姅 頃措嫻 韽靺橂摛鞚� General Atlantic (RP) Collections, LLC 氚� Delaware, Bermuda, Luxembourg鞐� 靹る霅� 氤奠垬鞚� General Atlantic 韴瀽 韼�霌� 氚� 氩曥澑鞚� 韱淀暣 氤挫湢霅橁碃 鞛堨潓鞚� 氚橃榿頃╇媹雼�. General Atlantic 瓿勳棿靷摛鞚� Rule 13d-5鞐� 霐半澕 攴鸽９鞚� 甑劚頃滊嫟瓿� 氚濏瀳瓿�, 韥措灅鞀� A鞕� 霃欕摫頃� 鞚奠姢韽爛毳� 靸濎劚頃橂姅 鞝勴櫂 旮半姤鞚� 瓿奠嫓頃╇媹雼�. 氤� 鞝滌稖靹滊姅 5% 旮办鞚� 齑堦臣頃橂姅 靻岇湢毳� 氤搓碃頃橃 鞎婌姷雼堧嫟.
Royalty Pharma plc est indiqu茅e dans ce Schedule 13G/A comme d茅tenant, via General Atlantic et des fonds affili茅s, certaines actions ordinaires de Classe A 脿 titre b茅n茅ficiaire. Collectivement, les personnes d茅clarante d茅tiennent un int茅r锚t indirect dans 14,243,870 actions ordinaires de Classe A (attribuables lors de la conversion d鈥檌nt茅r锚ts de Classe B), repr茅sentant environ 3.2% des actions ordinaires de Classe A en circulation, sur la base d鈥檜n total agr茅g茅 de 446,536,920 actions.
Le Schedule indique que les personnes d茅clarante disposent de 0 pouvoir exclusif de vote et de disposition et de 14,243,870 actions avec pouvoir partag茅 de vote et de disposition, ce qui refl猫te que les positions sont d茅tenues par l鈥檌nterm茅diaire de General Atlantic (RP) Collections, LLC et de plusieurs fonds et entit茅s d鈥檌nvestissement General Atlantic constitu茅s dans le Delaware, les Bermudes et le Luxembourg. Les entit茅s General Atlantic d茅clarent constituer un groupe au sens de la Rule 13d-5 et divulguent la clause de conversion qui cr茅e une exposition 茅quivalente 脿 la Classe A. Le d茅p么t ne signale pas de participation sup茅rieure au seuil de 5%.
Royalty Pharma plc wird in diesem Schedule 13G/A als wirtschaftlich Inhaber bestimmter Class-A-Stammaktien 眉ber General Atlantic und verbundene Fonds ausgewiesen. Zusammen halten die meldenden Personen ein indirektes Interesse an 14,243,870 Class-A-Stammaktien (ausgebbar bei Umwandlung von Class-B-Beteiligungen), was bei einer Gesamtanzahl von 446,536,920 Aktien etwa 3.2% der ausgegebenen Class-A-Aktien entspricht.
Der Schedule f眉hrt aus, dass die meldenden Personen 0 alleiniges Stimm- und Verf眉gungsrecht und 14,243,870 Aktien gemeinschaftliches Stimm- und Verf眉gungsrecht haben, was widerspiegelt, dass die Positionen 眉ber General Atlantic (RP) Collections, LLC und mehrere in Delaware, Bermuda und Luxembourg gegr眉ndete General Atlantic-Investmentfonds und -Einheiten gehalten werden. Die General Atlantic-Einheiten geben an, nach Rule 13d-5 eine Gruppe zu bilden und legen die Umwandlungsbestimmung offen, die eine gleichwertige Class-A-Exponierung erzeugt. Die Einreichung berichtet keinen Anteil 眉ber der 5%-Schwelle.
FAQ
How many shares does General Atlantic report beneficially owning in RPRX?
What percent of Royalty Pharma (RPRX) does that represent?
Do the Reporting Persons have sole voting power over these RPRX shares?
Which General Atlantic entity holds the convertible interests in RPRX?
Is this a group filing and what does that mean for RPRX investors?
